fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Terbinafine HCL

All products: general benefit

Lamisil · DIN 02031094 · 1% · Cr

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Lamisil · DIN 02031094 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 1999-02-23 · brand LAMISIL · ATC D01AE15 TERBINAFINE · form Cream · route Topical · ingredients TERBINAFINE HYDROCHLORIDE 1 %/% · company Cardinal health canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Lamisil: Formulary list price $0.67 per unit (the source does not state the unit; exact figure $0.6727). What the ministry pays, not the patient.

Ministry pays: $0.6727 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02031094)

Source record
DIN 02031094: Lamisil Raw flags: sec3=Y Item: 840408047; group id 824; item number 2009; lccId None; manufacturer id NOV Source form: Cr; strength: 1% Recorded listing: General benefit Source prices (unrounded): $0.6727; ministry $0.6727 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02031094 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14532
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02031094
Shortage record checked October 6, 2026

Other products in the same Health Canada class (D01A, D01AE): coverage varies; not interchangeable

  • Ciclopirox (Penlac): not a benefit
  • Clotrimazole (Clotrimaderm): general benefit, not a benefit
  • Ketoconazole (Nizoral): general benefit, not a benefit
  • Miconazole nitrate (Micatin): general benefit
  • Nystatin (Mycostatin): general benefit, not a benefit
  • Betamethasone dipropionate + clotrimazole (Lotriderm Cream): not a benefit
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE Some products covered without a code (check the product listing): CLOTRIMAZOLE, KETOCONAZOLE, NYSTATIN, TERCONAZOLE 84:04:08 Fungicides

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App

KETOCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Cr

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% w/w & 0.05% w/w · Top Cr

TERCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.4% · Vag Cr

FLUCONAZOLE

· 9 products · Limited Use, codes 235 · strengths: 150mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS LAMISIL® (terbinafine hydrochloride) is indicated for:  the treatment of fungal infections of the skin and nails caused by dermatophytes such as Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis, Epidermophyton floccosum and yeasts of the genus Candida (eg. C. albicans), as well as Malassezia furfur. LAMISIL tablets:  the treatment of onychomycosis (fungal infection of the nail) caused by dermatophyte fungi. o Prior to initiating treatment with LAMISIL® tablets, appropriate nail or skin specimens should be obtained for laboratory testing (KOH preparation, fungal culture, or nail biopsy) in order to confirm the diagnosis of onychomycosis or dermatomycosis.  may be considered for the treatment of severe tineal skin infections (tinea corporis, tinea cruris and tinea pedis) which have been unresponsive to topical treatment. Note: LAMISIL tablets are not effective in pityriasis versicolor (also known as Tinea versicolor). LAMISIL cream and spray:  Cream o the treatment of fungal infections of the skin caused by dermatophytes such as tric… https://pdf.hres.ca/dpd_pm/00067056.PDF PM date: December 31, 1993 Source product: LAMISIL; DIN 02031094; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.